Substance abuse treatment and receipt of liver specialty care among persons coinfected with HIV/HCV who have alcohol problems

Journal of Substance Abuse Treatment

Volumn 31, Issue 4, 2006, Pages 411-417

  Palepu, Anita ^a   Cheng, Debbie M ^b   Kim, Theresa ^c   Nunes, David ^c   Vidaver, John ^d   Alperen, Julie ^b   Saitz, Richard ^b   Samet, Jeffrey H ^b  

^a ST PAUL S HOSPITAL   (Canada)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DM STAT Inc   (United States)

Author keywords

Hepatitis C virus; Liver specialty care; Substance abuse; Substance abuse treatment

Indexed keywords

ALCOHOL; METHADONE;

ADULT; ALCOHOLISM; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG DEPENDENCE TREATMENT; FEMALE; FOLLOW UP; HALFWAY HOUSE; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH SERVICE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MENTAL HEALTH CARE PERSONNEL; METHADONE TREATMENT; MULTIVARIATE ANALYSIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUESTIONNAIRE; RESIDENTIAL HOME; RISK; STATISTICAL SIGNIFICANCE; SUBSTANCE ABUSE;

ADULT; ALCOHOLISM; COHORT STUDIES; COMBINED MODALITY THERAPY; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; GASTROENTEROLOGY; HALFWAY HOUSES; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER FUNCTION TESTS; LONGITUDINAL STUDIES; MALE; MASSACHUSETTS; METHADONE; MIDDLE AGED; PATIENT CARE TEAM; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; QUALITY ASSURANCE, HEALTH CARE; REFERRAL AND CONSULTATION; RESIDENTIAL TREATMENT; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS;

EID: 33751042226     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2006.05.015     Document Type: Article

References (46)

1. Andresen E.M., Malmgren J.A., Carter W.B., and Patrick D.L. Screening for depression in well older adults-Evaluation of a short-form of the CES-D. American Journal of Preventive Medicine 10 (1994) 77-84
2. Astone J.M., Strauss S.M., Hagan H., and Jarlais D.C.D. Outpatient drug treatment program directors' hepatitis C-related beliefs and their relationship to the provision of HCV services. American Journal of Drug and Alcohol Abuse 30 (2004) 783-797
3. Bica I., McGovern B., Dhar R., Stone D., McGowan K., Scheib R., et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clinical Infectious Diseases 32 (2001) 492-497
4. Buchsbaum D.G., Buchanan R.G., Centor R.M., Schnoll S.H., and Lawton M.J. Screening for alcohol-abuse using cage scores and likelihood ratios. Annals of Internal Medicine 115 (1991) 774-777
5. Chung R.T., Andersen J., Volberding P., Robbins G.K., Liu T., Sherman K.E., et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. New England Journal of Medicine 351 (2004) 451-459
6. Clanon K.A., Mueller J.J., and Harank M. Integrating treatment for hepatitis C virus infection into an HIV clinic. Clinical Infectious Diseases 40 (2005) S362-S366
7. Corrao G., and Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 27 (1998) 914-919
8. Desmond C.P., Roberts S.K., Dudley F., Mitchell J., Day C., Nguyen S., et al. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. Journal of Viral Hepatitis 13 (2006) 311-315
9. Edlin B.R., Seal K.H., Lorvick J., Kral A.H., Ciccarone D.H., Moore L.D., et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?. New England Journal of Medicine 345 (2001) 211-214
10. Flanigan T.P., Taylor L.E., and Mitty J.A. Use of community-based, directly observed therapy for HIV infection: Lessons learned for treatment of hepatitis C virus infection. Clinical Infectious Diseases 40 (2005) S346-S348
11. Fleming C.A., Tumilty S., Murray J.E., and Nunes D. Challenges in the treatment of patients co-infected with HIV and hepatitis C virus: Need for team care. Clinical Infectious Diseases 40 (2005) S349-S354
12. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12 (1975) 189-198
13. Graham C.S., Baden L.R., Yu E., Mrus J.M., Carnie J., Heeren T., et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clinical Infectious Diseases 33 (2001) 562-569
14. Hogg R.S., Yip B., Kully C., Craib K.J., O'Shaughnessy M.V., Schechter M.T., et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. Canadian Medical Association Journal 160 (1999) 659-665
15. Laine C., Hauck W.W., Gourevitch M.N., Rothman J., Cohen C., and Turner B.J. Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs. Journal of the American Medical Association 285 (2001) 2355-2362
16. Liang K.Y., and Zeger S.Y. Longitudinal data analysis using generalized linear models. Biometrika 73 (1986) 13-22
17. Litwin A.H., Soloway I., and Gourevitch M.N. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: Challenges and opportunities. Clinical Infectious Diseases 40 (2005) S339-S345
18. McLellan A.T., Cassiola J., Griffith J., Evans F., Bass H.L., and O'Brien C.P. New data from the addiction severity index: Reliability and validity in three centers. Journal of Nervous and Mental Disease 173 (1985) 412-423
19. Monga H.K., Rodriguez-Barradas M.C., Breaux K., Khattak K., Troisi C.L., Velez M., et al. Hepatitis C virus infection-Related morbidity and mortality among patients with human immunodeficiency virus infection. Clinical Infectious Diseases 33 (2001) 240-247
20. Munoz-Plaza C.E., Strauss S.M., Astone J.M., Jarlais D.C., and Hagan H. Drug treatment programs as sites of opportunity for the delivery of hepatitis C prevention education: Client and staff perspectives. Journal of Drug Issues 34 (2004) 861-878
21. National Institutes of Health. NIH consensus development conference statement: Management of hepatitis C. Gastroenterology 123 (2002) 2082-2099
22. Navaline H.A., Snider E.C., Petro C.J., Tobin D., Metzger D., Alterman A.I., et al. Preparations for AIDS vaccine trials. An automated version of the risk assessment battery (RAB): Enhancing the assessment of risk behaviors. AIDS Research and Human Retroviruses 10 Suppl 2 (1994) S281-S283
23. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. New England Journal of Medicine 338 (1998) 853-860
24. Palepu A., Horton N.J., Tibbetts N., Meli S., and Samet J.H. Substance abuse treatment and hospitalization among a cohort of HIV-infected individuals with alcohol problems. Alcoholism: Clinical and Experimental Research 29 (2005) 389-394
25. Palepu A., Raj A., Horton N.J., Tibbetts N., Meli S., and Samet J.H. Substance abuse treatment and risk behaviors among HIV-infected persons with alcohol problems. Journal of Substance Abuse Treatment 28 (2005) 3-9
26. Palepu A., Tyndall M.W., Chan K., Wood E., Montaner J.S., and Hogg R.S. Initiating highly active antiretroviral therapy and continuity of HIV care: The impact of incarceration and prison release on adherence and HIV treatment outcomes. Antiviral Therapy 9 (2004) 713-719
27. Perez-Olmeda M., Nunez M., Romero M., Gonzalez J., Castro A., Arribas J.R., et al. Pegylated ifn-alpha 2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 17 (2003) 1023-1028
28. Pessione F., Degos F., Marcellin P., Duchatelle V., Njapoum C., Martinot-Peignoux M., et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 27 (1998) 1717-1722
29. Robbins G.K., De Gruttola V., Shafer R.W., Smeaton L.M., Snyder S.W., Pettinelli C., et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. New England Journal of Medicine 349 (2003) 2293-2303
30. Robins L.N., Wing J., Wittchen H.U., Helzer J.E., Babor T.F., Burke J., et al. The composite international diagnostic interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Archives of General Psychiatry 45 (1988) 1069-1077
31. Samet J.H., Libman H., LaBelle C., Steger K., Lewis R., Craven D.E., et al. A model clinic for the initial evaluation and establishment of primary care for persons infected with human immunodeficiency virus. Archives of Internal Medicine 155 (1995) 1629-1633
32. Soriano V., Sulkowski M., Bergin C., Hatzakis A., Cacoub P., Katlama C., et al. Care of patients with chronic hepatitis C and HIV co-infection: Recommendations from the HIV-HCV international panel. AIDS 16 (2002) 813-828
33. Strathdee S.A., Latka M., Campbell J., O'Driscoll P.T., Golub E.T., Kapadia F., et al. Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users. Clinical Infectious Diseases 40 (2005) S304-S312
34. Strauss S.M., Astone J.M., Des Jarlais D.C., and Hagan H. Integrating hepatitis C services into existing HIV services: The experiences of a sample of US drug treatment units. AIDS Patient Care and STDs 19 (2005) 78-88
35. Strauss S.M., Astone J.M., Hagan H., and Des Jarlais D.C. The content and comprehensiveness of hepatitis C education in methadone maintenance and drug-free treatment units. Journal of Urban Health 81 (2004) 38-47
36. Strauss S.M., Astone J.M., Jarlais D.C., and Hagan H. A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States. Drug and Alcohol Dependence 73 (2004) 227-236
37. Sulkowski M.S. Treatment algorithm for the management of hepatitis C in HIV-coinfected persons. Journal of Hepatology 44 1 Suppl (2006) S49-S55
38. Sulkowski M.S., Mast E.E., Seeff L.B., and Thomas D.L. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clinical Infectious Diseases 30 (2000) S77-S84
39. Sulkowski M.S., and Thomas D.L. Hepatitis C in the HIV-infected person. Annals of Internal Medicine 138 (2003) 197-207
40. Sylvestre D.L. Treating hepatitis C virus infection in active substance users. Clinical Infectious Diseases 40 (2005) S321-S324
41. Taylor L.E. Delivering care to injection drug users co-infected with HIV and hepatitis C virus. Clinical Infectious Diseases 40 (2005) S355-S361
42. Thomas D.L., Astemborski J., Rai R.M., Anania F.A., Schaeffer M., Galai N., et al. The natural history of hepatitis C virus infection: Host, viral, and environmental factors. Journal of the American Medical Association 284 (2000) 450-456
43. Vassilev Z.P., Strauss S.M., Astone J.M., Friedmann P.D., and Jarlais D.C.D. Provision of on-site medical care to patients with hepatitis C in drug treatment units. Journal of Health Care for the Poor and Underserved 15 (2004) 663-671
44. Walley A.Y., White M.C., Kushel M.B., Song Y.S., and Tulsky J.P. Knowledge of and interest in hepatitis C treatment at a methadone clinic. Journal of Substance Abuse Treatment 28 (2005) 181-187
45. Ware Jr. J., Kosinski M., and Keller S.D. A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Medical Care 34 (1996) 220-233
46. Zeger S.L., and Liang K.Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42 (1986) 121-130